EUCTR2014-004412-11-GBActive, not recruitingPhase 1
A Phase II Proof of Concept (PoC), Double-Blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VSN16R for the Treatment of Spasticity in Subjects with Multiple Sclerosis
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Canbex Therapeutics Ltd
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •Be between 18 and 70 years of age, inclusive and having given written informed consent.
- •Have a confirmed diagnosis of MS: either, relapsing remitting MS (RRMS), secondary progressive MS (SPMS) or primary progressive MS (PPMS) as per McDonald’s 2010 revised criteria (Polman, 2011).
- •Have an Expanded Disability Status Scale (EDSS) = than 6.5 at screening.
- •Spasticity due to MS of at least 3 months duration, which is not wholly relieved with current anti-spasticity therapy, and which is expected to remain stable for the duration of the study.
- •A minimum score = 4 in the NRS for spasticity as rated by the subject at screening.
- •A minimum mean score of =2 on the Ashworth spasticity scale in at least 2 lower extremity muscle groups and a total mASH score of, at least, 4 in the lower extremity muscles tested at screening.
- •Normal renal function (estimated CrCl > 60ml/min). Normal hepatic function.
- •Women of childbearing potential (i.e., those not postmenopausal or surgically sterile) may participate provided that they are using adequate birth control methods (including barrier methods, intrauterine device [IUD], and oral contraceptives) for the duration of the study. Women who are of child-bearing potential must continue to use contraception for at least 1 month after their last dose of study medication.
- •Men must use barrier contraception for the duration of the study and continue to use it for at least 1 month after their last dose of study medication.
- •Willing and able to perform all procedures related to the clinical trial and to provide informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 138
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
Exclusion Criteria
- •Acute MS relapse requiring treatment with steroids within 30 days of screening.
- •Initiation or discontinuation of MS disease modifying treatment (DMT) within 30 days of screening.
- •Receiving medications that would potentially interfere with the actions of the study medication or outcome variables, including antispastic medications like baclofen, tizanidine, botulinum toxin, cannabinoids, benzodiazepines, gabapentin, pregabalin, smoked cannabis etc.
- •Any concomitant disease or disorder that has spasticity-like symptoms or that may influence the subject's level of spasticity.
- •Changes in chronic oral medications within 4 weeks of baseline and during study
- •Significant abnormalities in screening lab parameters (e.g., alanine aminotransferase [ALT], aspartate aminotransferase [AST], bilirubin > 2 ×upper limit of normal [ULN]; creatinine > 2mg/dl; white blood cell [WBC] < 2,300; platelets < 80,000).
- •Previous history of dementia, unstable psychiatric disease, or current signs and symptoms of significant medical disorders such as severe, progressive, or uncontrolled renal, hepatic, haematological, endocrine, pulmonary, cardiac, neurological, or cerebral disease.
- •Women who are pregnant or breastfeeding.
- •History of substance abuse within the past 12 months.
- •Participation in another clinical trial within 30 days of V1.
- •Subjects who are uncooperative or unwilling to sign consent form.
Investigators
Similar Trials
Active, not recruiting
Phase 1
A Proof of Concept, Phase 2a, Double-blind, Parallel Group, Randomised, Placebo controlled Study to Assess the Effect of Lanthanum Carbonate on intact FGF23 in Normo-phosphataemic Subjects with Stage 3 Chronic Kidney DiseaseChronic Kidney DiseaseEUCTR2009-016531-35-FRShire Pharmaceutical Development Ltd45
Not yet recruiting
Phase 2
A clinical trial to study the effects of Ayurvedic formulation containing Ashwagandha and Guduchi in improving the quality of life in patients of breast cancer receiving chemotherapy as treatmentCTRI/2008/091/000052Council of Scientific & Industrial Research, New Delhi60
Not yet recruiting
Phase 2
A clinical trial to study the effects of 2 Ayurvedic formulations, containing Ashwagandha, Brahmi and Amalaki on the physical and emotional well-being of elderly subjects.CTRI/2008/091/000047Council of Scientific & Industrial Research, New Delhi180
Active, not recruiting
Not Applicable
A Phase II Proof-of-Concept, Randomized, Double-blind, Vehicle-controlled Study, Including an Open-label Comparison to an Active Control, To Assess the Efficacy and Safety/Tolerability of Topical Riluzole in Patients with Stable Plaque-type Psoriasis - BF-37 in stable plaque-type psoriasisEUCTR2007-007037-39-DEBiofrontera Bioscience GmbH
Active, not recruiting
Phase 1
A phase 2a proof of concept, randomised, double-blind, placebo-controlled study to evaluate the safety/tolerability and efficacy of 4 subcutaneous injections of namilumab (150 mg) given over 10 weeks in subjects with moderate-to-severely active axial spondyloarthritis including those previously exposed to anti-TNF therapy (NAMASTE study)moderate-to-severe axial spondyloarthritisMedDRA version: 20.0Level: PTClassification code 10071400Term: Axial spondyloarthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2018-000176-15-GBIzana Bioscience Limited42